Does Nicotine Cause Inflammation?

Nicotine both suppresses and promotes inflammation, and which effect dominates depends on the tissue involved, the dose, how long exposure lasts, and even biological sex. The molecule engages the same family of receptors throughout the body but triggers strikingly different downstream cascades in blood vessels, the brain, the lungs, and immune cells. Calling nicotine simply “inflammatory” or “anti-inflammatory” misses the point: it reshapes the immune landscape in ways that can calm one fire while lighting another.

The Anti-Inflammatory Pathway That Complicates Everything

The reason nicotine’s relationship with inflammation is so tangled starts with a receptor called the alpha-7 nicotinic acetylcholine receptor (α7nAChR). This receptor sits on macrophages, the immune cells that patrol tissue for threats and pump out inflammatory signals when they find them. When the vagus nerve fires, it releases acetylcholine, which binds α7nAChR and tells macrophages to dial down the alarm. Nicotine mimics acetylcholine well enough to flip that same switch. A foundational study in mice showed that vagus nerve stimulation suppressed production of tumor necrosis factor (TNF), a major inflammatory signal, in normal mice but failed completely in mice lacking the α7 receptor, establishing it as the gatekeeper of this pathway.¹

When researchers activate α7nAChR directly with nicotine, the anti-inflammatory effects are broad: lower levels of pro-inflammatory cytokines, reduced expression of molecules that recruit immune cells to sites of injury, and altered activation of immune cells in ways that favor a calmer baseline.² In a sepsis model, nicotine improved survival in mice by suppressing TNF and other mediators of runaway inflammation through an enzyme called heme oxygenase-1; when that enzyme was blocked, nicotine’s protective effect vanished.³

This is not a fringe finding. The cholinergic anti-inflammatory pathway is well documented, and it is one reason some researchers have explored nicotine-like compounds as potential treatments for conditions driven by overactive inflammation. But this pathway operates largely at the level of macrophages and certain immune signals. The rest of the body tells a different story.

Blood Vessels and the Pro-Inflammatory Side

While nicotine quiets macrophage alarm signals through α7nAChR, its effects on the cardiovascular system lean decisively toward damage. Nicotine triggers oxidative stress in blood vessel walls by activating enzymes that generate reactive oxygen species, impairs the production of nitric oxide (the molecule that keeps arteries relaxed and healthy), and promotes the assembly of protein complexes called inflammasomes that amplify local inflammation.⁴

Animal studies reinforce this picture. In obese rats given oral nicotine, blood vessel cells showed decreased production of protective nitric oxide and increased expression of oxidative stress markers. When researchers neutralized TNF released by macrophages from the nicotine-treated animals, some of the vascular damage was prevented, suggesting macrophage-derived inflammation was part of the mechanism.⁵ This is a useful illustration of the paradox: the same macrophages that nicotine can suppress through one receptor pathway end up contributing to vascular inflammation when the broader metabolic environment is unhealthy.

Nicotine also accelerates the process that builds arterial plaques. In atherosclerosis-prone mice, nicotine increased the expression of enzymes called matrix metalloproteinases (MMP-2 and MMP-9), which break down the structural scaffolding inside artery walls and destabilize plaques, making them more likely to rupture.⁶ Separately, at concentrations matching what a regular smoker’s blood carries, nicotine upregulated both VCAM-1 (an adhesion molecule that glues immune cells to vessel walls) and MMP-2/MMP-9 in macrophages and smooth muscle cells through the α7nAChR-JNK signaling pathway.⁷ The same α7 receptor that dampens systemic cytokine release can, in a different cell type and signaling context, promote vascular inflammation.

What Happens in the Brain

Microglia are the resident immune cells of the central nervous system, and nicotine changes their behavior in ways that depend on timing, sex, and whether the drug is still present or has been withdrawn. In a proteomics study of mice chronically exposed to nicotine, cerebellar microglia showed altered protein profiles in a sex-dependent pattern: males had shifts in metabolic and structural proteins, while females showed changes in complement proteins, part of the immune system’s early-warning machinery.⁸

In the context of cancer, nicotine pushed microglia toward an “M2” state, a profile associated with tissue repair but also with immune suppression. By activating the STAT3 signaling pathway, nicotine increased the expression of M2 markers while suppressing the more aggressive M1 markers. In animal models, this shift made the brain more hospitable to metastatic tumors.⁹

Withdrawal from nicotine adds another layer. A study examining the brain’s reward center, the nucleus accumbens, found that both active nicotine use and withdrawal changed microglial shape, but the inflammatory consequences differed sharply. Pro-inflammatory signaling and anxiety-like behavior appeared only during withdrawal, not during active exposure. When microglia were pharmacologically depleted during withdrawal, both the inflammatory spike and the anxious behavior were prevented.¹⁰ The implication is worth sitting with: some of the neuroinflammation people associate with nicotine use may actually be a feature of quitting rather than of the drug itself.

How Nicotine Reprograms Immune Cells

Beyond the cholinergic anti-inflammatory pathway, nicotine reshapes how immune cells develop and behave. Macrophages can exist along a spectrum between M1 (pro-inflammatory, geared for pathogen killing) and M2 (anti-inflammatory, geared for tissue repair and immune suppression). Nicotine consistently pushes macrophages toward the M2 end. In lab-cultured macrophages, nicotine induced M2 polarization in a dose-dependent manner, producing a mixed profile associated with tissue repair and blood vessel growth.¹¹ In the context of lung cancer, a similar M2 shift was driven through a different nicotinic receptor subtype (α5-nAChR) and was linked to tumor progression.¹²

Dendritic cells, which act as intermediaries between the innate and adaptive immune systems, are also affected. In a nicotine-rich environment, dendritic cells derived from human monocytes showed reduced ability to take up pathogens, produced less of the cytokine that drives strong immune responses against intracellular threats, and were worse at stimulating T cells.¹³ These dendritic cells also failed to properly express surface molecules needed for presenting foreign material to the adaptive immune system, and they lost the ability to promote the type of T cell response most useful against viruses and bacteria.¹⁴ At the molecular level, nicotine suppressed the expression of signaling molecules involved in dendritic cell maturation and T cell activation.¹⁵

The practical consequence of this immune cell reprogramming is that nicotine can simultaneously reduce the kind of inflammation that causes tissue damage in autoimmune diseases and weaken the kind of immune surveillance that catches infections and early-stage cancers. Whether that trade-off is net positive or negative depends entirely on what disease process you are worried about.

Neutrophils, Sticky Traps, and Autoimmune Risk

Neutrophils, the most abundant white blood cells, have their own complicated response to nicotine. When activated, neutrophils can expel webs of DNA and antimicrobial proteins called neutrophil extracellular traps (NETs). These traps are useful for catching pathogens but can also damage surrounding tissue and fuel autoimmune reactions when produced excessively. Nicotine induces NET formation in a dose-dependent fashion through nicotinic acetylcholine receptors.¹⁶

This matters for autoimmune disease. In rheumatoid arthritis research, nicotine-induced NET formation synergized with autoantibody complexes and TNF to amplify the response, and blocking the α7nAChR on neutrophils reduced NET release.¹⁷ Smoking is one of the strongest environmental risk factors for rheumatoid arthritis, and nicotine-driven NETosis may be part of the reason.

Yet even here, the picture has a contradictory thread. Studies of nicotine’s effect on T cell subsets in rheumatoid arthritis patients found that it suppressed the differentiation of Th17 cells, a subset strongly implicated in autoimmune inflammation, while promoting Th2 cells and helping correct the Th1/Th2 imbalance typical of the disease.¹⁸ The cholinergic pathway also increases regulatory T cells, the cells responsible for keeping autoimmune responses in check.¹⁹ So nicotine can prime neutrophils to launch an autoimmune-friendly attack while simultaneously recruiting the T cell subsets that restrain autoimmune damage. The net outcome likely depends on disease stage, genetic predisposition, and dose.

Lungs, Gums, and Local Tissue Responses

In the lungs, nicotine dampens the sensors that recognize invading microbes. When human lung epithelial cells and macrophages were exposed to nicotine, they produced fewer of the receptors (TLR-2, TLR-4, NOD-2) that detect bacterial components. During tuberculosis infection, nicotine-exposed lung cells released lower levels of key chemokines and cytokines, including TNF-α and several signals needed to recruit additional immune cells to the infection site.²⁰ This is the anti-inflammatory pathway working against you: less inflammation sounds good until the inflammation you are suppressing was actually needed to contain a serious infection.

In the mouth, nicotine acts more directly as an inflammatory irritant. When human periodontal ligament cells were exposed to nicotine, they significantly increased their release of IL-1β and IL-8, two cytokines that drive the tissue destruction seen in gum disease. This effect was mediated through α7nAChR and involved a cellular cleanup process called autophagy; when autophagy was blocked, the inflammatory cytokine release was reduced.²¹ Smokers’ well-documented vulnerability to periodontal disease has multiple causes, but nicotine’s direct stimulation of gum tissue inflammation is clearly one of them.

What Nicotine Replacement Therapy Reveals

If nicotine itself were the primary driver of smoking-related inflammation, you would expect people using nicotine replacement therapy (NRT) after quitting to show slower improvement in inflammatory markers compared to people who quit without any nicotine replacement. That is not what researchers have found. In a study assessing biomarkers of inflammation, endothelial function, oxidative stress, and lipids in people who quit smoking, there was no difference in biomarker changes between those who used NRT and those who did not.²²

A separate study of healthy smokers tracked endothelial function, arterial stiffness, and inflammatory markers over three months. Those who quit smoking entirely showed significant improvements across the board, including reduced levels of IL-1β and sICAM-1 (a marker of vascular inflammation), while those who did not fully abstain saw no change.²³ The key finding here: the people who quit with the help of NRT improved just as much as those who quit without it. At the clinical level, nicotine delivered cleanly through a patch or gum does not appear to perpetuate the inflammatory burden of smoking.

This lines up with the understanding that cigarette smoke contains thousands of compounds beyond nicotine, many of which are directly toxic and pro-inflammatory. E-cigarette research points in a similar direction. A study in female mice found that the propylene glycol and vegetable glycerin aerosol base used in e-cigarettes caused endothelial dysfunction independent of nicotine or flavorings, driven by aldehydes formed when the solvents are heated.²⁴ The delivery vehicle matters at least as much as the nicotine it carries.

Metabolic Inflammation and Body Fat

Obesity produces chronic low-grade inflammation in fat tissue, driven partly by macrophages that infiltrate and become activated there. Nicotine’s interaction with this process highlights the anti-inflammatory pathway in a more favorable light. In genetically obese and diet-induced obese mice, nicotine improved insulin sensitivity and suppressed adipose tissue inflammation through α7nAChR. Macrophages from mice lacking the α7 receptor produced far more inflammatory cytokines in response to fatty acids and TNF, and these receptor-deficient mice had worse insulin sensitivity and more inflamed fat tissue than normal mice.²⁵

In non-obese animals, the picture shifted. A study found that in lean mice, nicotine’s improvement of insulin sensitivity did not appear to involve inflammation at all. Inflammatory cytokine levels in fat tissue and muscle were already very low in these animals and did not differ between nicotine-treated and untreated groups.²⁶ The anti-inflammatory benefit of nicotine in fat tissue seems to require pre-existing inflammation to suppress. If the tissue is not inflamed to begin with, there is nothing for the cholinergic pathway to turn down.

Sex Differences in Nicotine’s Immune Effects

The way nicotine reshapes inflammation is not identical in males and females. As noted earlier, chronic nicotine altered microglial protein profiles differently by sex, with males showing metabolic changes and females showing complement-related adaptations.⁸ A review of studies testing the interaction between sex and tobacco or nicotine on inflammation found that males and females generally exhibited different immune responses, though the specific pattern varied between rodent and human studies and across different methods of measuring inflammation.²⁷

This is an area where the evidence is thin enough that drawing firm practical conclusions is premature. But it is worth knowing that blanket statements about nicotine and inflammation may apply more strongly to one sex than the other. Women metabolize nicotine faster than men and have different baseline immune profiles, both of which could shift the balance between nicotine’s anti-inflammatory and pro-inflammatory effects.

Prenatal Exposure and Lasting Inflammatory Changes

One scenario where nicotine’s inflammatory effects appear less ambiguous is prenatal exposure. In a rat model, offspring of mothers exposed to nicotine during pregnancy and breastfeeding showed signs of oxidative stress and inflammatory changes in their ovaries as adults, including elevated IL-1β and increased expression of inflammation-related proteins, alongside reduced mast cell populations.²⁸ The long delay between exposure and measurable damage suggests that nicotine during development may program lasting changes in immune function rather than causing acute inflammation that resolves once the drug clears.

In a separate line of research, long-term e-cigarette exposure in mice produced dose-dependent changes in DNA methylation across nearly 9,000 sites, with enrichment in inflammatory signaling pathways. This correlated with increased cytokine gene expression, pointing to an epigenetic route through which chronic nicotine exposure could embed inflammatory tendencies into cells’ programming.²⁹ Whether these methylation changes translate to clinically meaningful inflammation in humans remains an open question, but they suggest the inflammatory footprint of nicotine may extend beyond what any single blood test can capture.

Why the Dose and the Context Keep Mattering

One of the more underappreciated findings in this research is that nicotine’s effects on inflammatory markers are not always linear. In studies of vascular smooth muscle cells and macrophages, low nicotine concentrations (matching the blood levels of a typical smoker) increased the expression of inflammatory adhesion molecules and matrix metalloproteinases, while much higher concentrations actually inhibited them.⁷ This inverted dose response complicates any simple narrative. In some tissues, moderate exposure drives inflammation while higher exposure suppresses it.

The tissue context matters just as much. Nicotine increased inflammatory cytokines in gum tissue cells while simultaneously reducing them in lung macrophages during tuberculosis infection. It suppressed macrophage activation in fat tissue of obese animals while promoting endothelial dysfunction in blood vessels of those same animals. Wound-healing cells (mesenchymal stromal cells) showed a trend toward increased IL-6 secretion with rising nicotine doses, but the change did not reach statistical significance, while cigarette smoke extract produced significant inflammatory effects in the same cell type.³⁰ That gap between nicotine alone and whole smoke reinforces the clinical NRT findings: in the messy real world of human bodies, nicotine by itself appears to be a milder inflammatory actor than the combustion products it typically travels with.

None of this means nicotine is harmless. It is addictive, it raises heart rate and blood pressure acutely, and the evidence for vascular damage, neutrophil trap formation, and immune suppression in the lungs is real. But the question of whether nicotine “causes inflammation” resists a yes-or-no answer because the molecule genuinely does opposite things depending on where in the body you look and what you measure. Any health decision about nicotine products should account for that complexity rather than assume inflammation is a single toggle that nicotine flips one way.